112 related articles for article (PubMed ID: 7546045)
1. Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
Czejka M; Bandak S; Simon D; Schüller J; Weiss C; Schernhammer E
Z Naturforsch C J Biosci; 1995; 50(7-8):565-70. PubMed ID: 7546045
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells.
Bandak S; Czejka M; Schüller J; Schernhammer E
Arzneimittelforschung; 1995 Feb; 45(2):212-5. PubMed ID: 7710452
[TBL] [Abstract][Full Text] [Related]
3. [Binding of epirubicin to human plasma protein and erythrocytes: interaction with the cytoprotective amifostine].
Pernkopf I; Tesch G; Dempe K; Kletzl H; Schüller J; Czejka M
Pharmazie; 1996 Nov; 51(11):897-901. PubMed ID: 9036391
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
Scheithauer W; Schenk T; Czejka M
Br J Cancer; 1993 Jul; 68(1):8-9. PubMed ID: 8318424
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
Yang RX; Ren HX; Zhuang L; Gao CL; Dong C; Luo CX; Wang XN; Feng EF; He JC
Arzneimittelforschung; 2012 Dec; 62(12):677-81. PubMed ID: 23203544
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins.
Bandak S; Czejka M; Schüller J
Z Naturforsch C J Biosci; 1994; 49(7-8):483-8. PubMed ID: 7945673
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Lehnert M; Mross K; Schueller J; Thuerlimann B; Kroeger N; Kupper H
Br J Cancer; 1998 Apr; 77(7):1155-63. PubMed ID: 9569055
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
[TBL] [Abstract][Full Text] [Related]
10. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Ralph LD; Thomson AH; Dobbs NA; Twelves C
Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
[TBL] [Abstract][Full Text] [Related]
11. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
Jakobsen P; Steiness E; Bastholt L; Dalmark M; Lorenzen A; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS
Cancer Chemother Pharmacol; 1991; 28(1):63-8. PubMed ID: 2040035
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
[TBL] [Abstract][Full Text] [Related]
14. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Gurney HP; Ackland S; Gebski V; Farrell G
J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.
Hu OY; Chang SP; Jame JM; Chen KY
Cancer Chemother Pharmacol; 1989; 24(5):332-7. PubMed ID: 2758564
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Jakobsen P; Sørensen B; Bastholt L; Mirza MR; Gjedde SB; Mouridsen HT; Rose C
Cancer Chemother Pharmacol; 1994; 35(1):45-52. PubMed ID: 7987976
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer.
Chan S; Campone M; Santoro A; Conte PF; Bostnavaron M; Nguyen L
Cancer Chemother Pharmacol; 2014 May; 73(5):903-10. PubMed ID: 24627219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
